Silibinin is a direct STAT3 targeting agent, which can not only reduce therapy-associated nephrotoxicity, neurotoxicity and cardiotoxicity in preclinical models but also has the potential to reverse cancer cell drug resistance (Bosch-Barrera et al., 2017). The gene discussed is STAT3; the disease is cancer.